Publications by authors named "Magdalena A Benda"
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in hematological patients under real-life conditions.
View Article and Find Full Text PDFArticle Synopsis
- Multiple myeloma (MM) is a complex cancer that requires multiple treatment lines due to frequent relapses, with varying attrition rates reported.
- A study of 571 patients from the Austrian Myeloma Registry found that around 43.6% underwent stem cell transplantation and that appropriate frontline treatment significantly reduced attrition rates.
- Factors such as younger age and achieving deep remission after treatment correlated with better long-term outcomes, suggesting that access to effective medications plays a crucial role in managing MM.
Background: Hemodialysis patients are at high risk for severe COVID-19. SARS-CoV-2 vaccination related safety and immunogenicity data in these patients are rare.
Methods: In this observational study SARS-CoV-2-seronegative hemodialysis patients were vaccinated with two doses of the Pfizer/BioNTech mRNA-BNT162b2 vaccine (COMIRNATY 30 µg) and followed for 90 days.